Scientific Symposia at ATS 2025 Examine New Results from Longitudinal Studies in Asthma

3 minutes

According to recent Center for Disease Control (CDC) data, nearly 25 million people in the United States have been diagnosed with asthma. While the volume of individuals affected is high, recent investments in research and subsequent advancements in care have engendered a prevailing optimism in the field that critical progress is being made to help patients struggling with the disease.

Rachel Scheraga, MD, ATSF
Rachel Scheraga, MD, ATSF

The Allergy, Immunology, and Inflammation (All) Assembly has curated a robust lineup of educational opportunities at the ATS 2025 International Conference for professionals of all ages interested in exploring recent developments and the future of asthma management.

“NIH-funded consortiums and adopting a ‘team science’ approach to study diseases like asthma have paved the way for many new drugs in my relatively short time seeing these patients,” explained Rachel Scheraga, MD, ATSF, associate professor of medicine in the Cleveland Clinic Lerner College of Medicine and program chair for the All Assembly. “I would say the care is advancing more rapidly than nearly any other pulmonary disease we study.”

Several scientific symposia sessions will share results in asthma research from recent significant studies, such as “25 Years of Severe Asthma Research Program: Discoveries and Beyond” at 8:15 a.m. PT on Wednesday, May 21. The Severe Asthma Research Program (SARP) is a 25-year observational study investigating biological mechanisms in severe asthma, making it the longest-running research program involving patients with severe asthma. SARP has comprehensively characterized severe asthma patients, identified severe asthma clinical and molecular phenotypes, and uncovered novel pathophysiobiologic mechanisms. This scientific symposium will review discoveries from SARP, including phenotypes, exacerbations, biomarkers, and imaging, while also exploring the impact of clinical practice changes and the COVID-19 pandemic.

“SARP has released updates nearly every year, but it’s going to be really exciting to see where they are with their longitudinal outcomes after 25 years of following severe asthma patients,” said Yvonne Huang, MD, ATSF, associate professor in the Departments of Internal Medicine and Microbiology/Immunology at the University of Michigan – Ann Arbor, and program chair-elect for the All Assembly.

Yvonne Huang, MD, ATSF
Yvonne Huang, MD, ATSF

New results from a more recent study will also be shared during the scientific symposia session, “Precision Medicine in Severe Asthma: Late-Breaking Results From the PrecISE Trial,” hosted at 9:15 a.m. on Monday, May 19. This session will share the results of the Precision Interventions in Severe and Exacerbation Prone Asthma (PrecISE) clinical trial for the first time. PrecISE started in 2019 and used an innovative multi-stage crossover trial design that tested five novel interventions in adults and adolescents with severe asthma.

“The results from PrecISE have been long-awaited for several years, so we anticipate exciting findings to be reported during this symposium,” Dr. Huang said.

For attendees interested in exploring new data related to the inflammatory pathways in asthma, the scientific symposium, “How Novel Inflammatory Interactions in Asthma Contribute to Disease and Severity,” beginning at 2:15 p.m. on Tuesday, May 20, will explore non-Type-2 pathways in asthma and how they contribute to disease. The symposium will also examine how the interaction of non-Type 2 inflammatory pathways with Type-2 inflammation and with each other may contribute to severe asthma and complicate the response to current asthma therapies.

In addition to the lineup of scientific symposia sessions focused on asthma, ATS 2025 will also feature Meet the Expert sessions like “Has the Time Come to Aim for Asthma Remission?” and “Advanced Use of Asthma Biologics: A Case-Based Master Class” for attendees interested in diving deeper into recent asthma research. Pre-registration and a $100 fee are required to attend the Meet the Expert sessions. Attendance is limited, so enroll today to ensure your spot.

Throughout the conference, there will be numerous abstract and thematic poster presentations focused on asthma research, as well. Visit ATSConference365 to view the full listings.

Register Today for ATS 2025


Register today for the ATS 2025 International Conference! Don’t miss the opportunity to experience this year’s premier respiratory health conference, May 16-21 in San Francisco. Join your colleagues to learn about the latest pulmonary, critical care, and sleep medicine developments. Not an ATS member? Join today and save on your conference registration!